(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.47%) $27.23
(0.41%) $924.25
(0.32%) $0.935
(0.80%) $11.04
(0.18%) $0.801
(-0.32%) $91.87
@ $8.24
发出时间: 15 Feb 2024 @ 04:41
回报率: -36.13%
上一信号: Feb 14 - 04:50
上一信号:
回报率: 3.45 %
Live Chart Being Loaded With Signals
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases...
Stats | |
---|---|
今日成交量 | 1.20M |
平均成交量 | 1.21M |
市值 | 400.28M |
EPS | $0 ( 2024-02-15 ) |
下一个收益日期 | ( $-0.950 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.040 |
ATR14 | $0.00900 (0.17%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-11 | Cline Christopher R. | Sell | 54 | Common Stock |
2024-01-31 | Dube Eric M | Buy | 135 000 | Common Stock |
2024-02-01 | Dube Eric M | Sell | 9 106 | Common Stock |
2024-01-31 | Dube Eric M | Buy | 360 000 | Employee stock option (right to buy) |
2024-02-01 | Dube Eric M | Sell | 10 016 | Common Stock |
INSIDER POWER |
---|
89.26 |
Last 100 transactions |
Buy: 2 015 500 | Sell: 106 721 |
音量 相关性
Travere Therapeutics, 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Travere Therapeutics, 相关性 - 货币/商品
Travere Therapeutics, 财务报表
Annual | 2023 |
营收: | $145.24M |
毛利润: | $88.86M (61.18 %) |
EPS: | $-1.500 |
FY | 2023 |
营收: | $145.24M |
毛利润: | $88.86M (61.18 %) |
EPS: | $-1.500 |
FY | 2022 |
营收: | $212.02M |
毛利润: | $204.43M (96.42 %) |
EPS: | $-4.37 |
FY | 2021 |
营收: | $227.49M |
毛利润: | $220.71M (97.02 %) |
EPS: | $-3.79 |
Financial Reports:
No articles found.
Travere Therapeutics,
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。